Peptimmune tries to block competing generic Copaxones
This article was originally published in Scrip
Executive Summary
Privately held Peptimmune – developing what it terms a Phase Ib "next-generation Copaxone" - has filed a citizen's petition requesting that the US FDA should not approve any generic version of Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone (glatiramer acetate) without broad pharmacokinetic and pharmacodynamic data.